This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Complicated Urinary Tract Infections Treatment Market

Market Insights on Complicated Urinary Tract Infections Treatment covering sales outlook, demand forecast & up-to-date key trends

Complicated Urinary Tract Infections Treatment Market By Drug Class, Distribution Channel & Region | Forecast 2023 to 2033

Complicated Urinary Tract Infections treatment market Snapshot (2023 to 2033)

The global Complicated Urinary Tract Infections treatment market size is expected to surpass an impressive valuation of USD 9.2 billion in 2023 and is projected to reach USD 16.1 billion by 2033, trailing a CAGR of 5.76%

Due to the increase in drug-resistant bacteria and overuse of antibiotics, the prevalence of complicated urinary tract infections is expected to grow in the future which will fuel the market expansion of complicated urinary tract infection treatment. The increasing prescription of quinolones by doctors to treat complex UTI situations will propel market growth. Also, the use of Cephalosporin as a secondary treatment option will also aid in the market growth.

However, conflicting guidelines on complicated urinary tract infections issued by several organizations cause confusion among providers that will negatively impact the growth of the complicated urinary tract infection treatment market.

Report Attribute

Details

Expected Market Value (2023)

US$ 9.2 billion

Anticipated Forecast Value (2033)

US$ 16.1 billion

Projected Growth Rate (2023 to 2033)

CAGR 5.76%

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Complicated Urinary Tract Infections Demand Analysis vs. Forecast 2023 to 2033

The market for complicated urinary tract infection treatment was worth USD 7.6 billion in 2018 while growing at a CAGR of 3.9% during the historical period.

The high demand for antibiotics as they are the only treatment for complicated urinary tract infections and urinary tract infections will transform the market scenario.

There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market which will open up new avenues for the market. Furthermore, increasing mergers, acquisitions, and collaborations between companies to develop safe and effective drugs will drive the complicated urinary tract infections market growth.

Also, for treating complicated urinary tract infections, fluoroquinolones such as ciprofloxacin or ofloxacin are prescribed in case of less severe infection. Apart from these, the loss of patent rights of branded drugs and the availability of cost-effective antibiotics from generic companies are among the factors that are likely to spur the growth of the complicated urinary tract infection treatment market.

After a comprehensive analysis of the above-mentioned factors, the market for complicated Urinary tract infections treatment market is projected to reach USD 16.1 billion by 2033 with a CAGR of 5.76% during the forecast period.

Which are Some Prominent Drivers of the Complicated Urinary Tract Infections treatment market?

The arrival of pipeline therapies to drive market growth

The complicated urinary tract infections therapies in the pipeline include Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime-zidebactam (WCK-5222), Cefepime/Taniborbactam, Cefepime/Enmetazobactam, Fosfomycin (ZT-01/Contempo), Finafloxacin, and others. These therapies are expected to augment the growth of the Complicated urinary tract infections treatment market during the forecast period.

The growth in complicated urinary tract infections market size is also a direct consequence of a rise in research and development activity, a growing prevalent population, and the expected commercial success of upcoming therapies.

With increasing multidrug resistance and antibiotic overuse, the prevalence of complicated urinary tract infections is anticipated to rise in the future, leading to the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for complicated UTIs are expected to aid the complicated urinary tract infections market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

High cost and potential side effects to restrain market expansion

Inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus restraining the growth of the complicated urinary tract infections market. Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to hinder clinical trial study evaluation in the complicated urinary tract infections market.

As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis; complex regulatory requirements are anticipated to hamper the growth of the complicated urinary tract infections market.

Region-Wise Insights

What is the growth outlook in North America?

North America to lead the market with the maximum share

The Complicated urinary tract infections treatment market in this region is estimated to grow USD 5.29 billion by 2033, exhibiting a CAGR of 4% during the forecast period. It is estimated to hold a 32.9% industry share by end of the projected period. The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for complicated urinary tract infections which will fuel growth in this region.

Additionally, according to a study published in Therapeutic Advances in Urology in May 2020 titled An Introduction to the Epidemiology and Burden of Urinary Tract Infections, urinary tract infections (UTIs) are the most common outpatient infections in adult women, with a lifetime prevalence of 50-60%. Urinary tract infections are a substantial societal and personal burden, with complicated urinary tract infections accounting for a significant number of medical visits in the US each year. This condition is estimated to drive the market by increasing sales of urinary tract infection medicines in the region.

On the other hand, research, and development of novel classes of antibiotics for urinary tract infections are anticipated to aid in market expansion. In August 2020, for example, researchers at California Polytechnic State University announced the development of a new class of antibiotics for urinary tract infections that target bacterial iron acquisition.

Thus, all the above factors are expected to propel growth in the region during the forecast period.

What is the growth prospect in East Asia?

East Asia propelling growth at fastest CAGR

The market in East Asia is projected to be worth USD 3.2 billion by 2033 while growing at a CAGR of 5.1% during the forecast period. This region is estimated to account for around 20% market share by end of the forecast period. The growth is attributable to high investments in research and development departments by key players to combine and launch new medications that are tailored to the needs of the East-Asian market. Growth in the prevalence of hospital-acquired UTIs and technological advancements in testing instruments will drive growth. Furthermore, excellent reimbursement conditions and illness management will boost market expansion.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category wise Insights

By drug class, which segment will witness the fastest growth

Penicillin and combinations to reflect growth with the fastest CAGR

The penicillin and Combinations Segment is projected to grow with the fastest compounded annual growth rate of 7.9% during the forecast period. The growth is attributed to the rising prevalence of urinary tract infections (UTIs). Most penicillin’s widely being used directly and in combinations for treating urinary tract infections that are augmenting the segment’s growth.

Which segment will possess market hegemony by the drug class?

Quinolones fuelling segments growth with maximum share

This segment is estimated to hold around 48.6% market share by end of the forecast period. The growth is attributed to the surge in demand for novel UTI therapeutics. Quinolones represent a natural alternative to trimethoprim-sulfamethoxazole for treating urinary tract infections (UTIs) when resistance becomes a potential problem. Quinolones are broadly active against most Gram-negative and Gram-positive organisms, so that multi-drug resistance is avoided in the treatment of urinary tract infections. Thus, driving the segment’s growth.

Also, these drugs have the capability to improve quality of life and combat symptoms with high therapeutic effects. These lifesaving advantages of quinolones make them the most profitable and highly adopted products across regions that fuel the growth of the overall market.

By distribution channel, which segment will account for the maximum share?

Hospital pharmacies lead the segment with dominating share

This segment is estimated to dominate the market with a maximum market share of 51% by end of the forecast period. The growth is attributable to high investments in hospital infrastructure and faster adoption of various novel drugs for the treatment of complicated urinary tract infections.

Start-ups in Complicated Urinary Tract Infections treatment market

  • Founded in 2016, ‘ODx innovations’ is a United Kingdom-based start-up that provides rapid antibiotic susceptibility testing for Urinary Tract Infections (UTI). The company offers antimicrobial resistance and microbiological technology to diagnose bacterial infection and bacterial count in UTIs and provide antibiotic sensitivities of the isolated pathogen for treatment.
  • Founded in 2015, Biomedicals is a Molndal, Sweden-based start-up that develops smart medical devices for treating urinary tract infections. The company has developed a UTI-Q orally administered medical device that reduces the presence of E. Coli bacteria in adult people with urinary tract infections.
  • Founded in 2011, ‘Ideal Medical Solution’ is an Epsom, United Kingdom-based start-up that provides ultrasound nano-technology to prevent catheter-associated urinary tract infections. Its flagship product UroShield is an external medical device developed to prevent bacterial biofilm formation on urethral and suprapubic catheters by means of nonharmful ultraviolet rays.

Market Competition

The global Complicated Urinary Tract Infections treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allegra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, Allergan, Bayer AG, Pfizer, Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC

Some recent developments in this industry are:

  • In November 2020, Allergan announced the FDA acceptance of a Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
  • In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
  • In September 2021, BDR Pharma, one of India's leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 9.2 billion

Market Value in 2033

US$ 16.1 billion

Growth Rate

CAGR of 5.76% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD billion and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • By drug
  • By distribution channel
  • By Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Countries Profiled

  • United States of America
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • Malaysia
  • Singapore
  • Thailand
  • South Korea
  • Australia
  • New Zealand
  • UAE
  • South Africa
  • Israel
  • GCC countries

Key Companies Profiled

  • Spero Therapeutics
  • Wockhardt
  • Venatorx Pharmaceuticals
  • Allecra Therapeutics
  • Nabriva Therapeutics AG
  • MerLion Pharmaceuticals
  • Allergan
  • Bayer AG
  • Pfizer, Inc
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC

Customization

Available Upon Request

Key Segments Profiled in the Complicated Urinary Tract Infections treatment market Industry survey

Complicated Urinary Tract Infections treatment market by Drug class:

  • Penicillin and combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitro furans

Complicated Urinary Tract Infections treatment market by Distribution channel:

  • Hospital Pharmacies
  • Gynecology and Urology Clinics
  • Drug stores
  • Retail Pharmacies

Complicated Urinary Tract Infections treatment market by Region::

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

FMI projects the global Complicated Urinary Tract Infections treatment market to expand at a 5.76% value CAGR by 2033.

The global Complicated Urinary Tract Infections treatment market is expected to garner a market value of US$ 16.1 billion by 2033.

FMI has projected North America to be one of the most lucrative regions for Complicated Urinary Tract Infections treatment market.

East-Asia region is anticipated to grow fastest during the forecast period.

Table of Content

1. Executive Summary | Complicated Urinary Tract Infections Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Penicillin and Combinations

        5.3.2. Quinolones

        5.3.3. Cephalosporin

        5.3.4. Azoles and Amphotericin B

        5.3.5. Nitro furans

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Gynaecology and Urology Clinics

        6.3.3. Drug Stores

        6.3.4. Retail Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MIDDLE EAST AND AFRICA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States of America

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MIDDLE EAST AND AFRICA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. United States of America

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Spero Therapeutics

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Wockhardt

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Venatorx Pharmaceuticals

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Allecra Therapeutics

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Nabriva Therapeutics AG

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. MerLion Pharmaceuticals

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Allergan

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Bayer AG

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Pfizer, Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. GlaxoSmithKline plc

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Bristol-Myers Squibb Company

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Janssen Global Services, LLC

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 107: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 113: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 114: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 115: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 116: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Drug Class, 2023 to 2033

Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Urinary Tract Infection Testing Market

Published : August 2019

Healthcare

Urinary Tract Infection (UTI) Treatment Market

Published : June 2019

Google translate

Complicated Urinary Tract Infections Treatment Market